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A 49 years old woman (weight 68 kg, BMI 27.3 kg/m2) with heterozygous familial
hypercholesterolemia (HeFH) and multiple statin intolerance with muscle aches and
creatine kinase elevation, presented at the Outpatient Lipid Clinic of Verona Univer-
sity Hospital in May 2015. Hypercholesterolemia was firstly diagnosed during
adolescence, followed in adulthood by a diagnosis of Cogan’s syndrome, a rheumato-
logic disorder characterized by corneal and inner ear inflammation. No xanthomas,
corneal arcus, or vascular bruits were detectable at physical examination. Screening
for macrovascular complications did not reveal relevant damages. Ongoing medical
therapy included salicylic acid, methylprednisolone, methotrexate, and protonic-pump
inhibitor. In the absence of specific lipid-lowering therapy, plasma lipid levels at first
visit were: total-cholesterol5 522 mg/dL, LDL-cholesterol5 434 mg/dL, HDL-
cholesterol5 84 mg/dL, triglycerides5 120 mg/dL, Lp(a)5 13 mg/dL. On Decem-
ber 2015, evolocumab 140 mg sc every 2 weeks was initiated. After a 24-week
treatment, the LDL-cholesterol levels decreased by an average of 21.2% to 3426
22 mg/dL (mean6 SD). On May 2016, LDL-apheresis (H.E.L.P.system) was started
as add-on therapy. Compared to the average levels obtained during the evolocumab
monotherapy period, the LDL-cholesterol was reduced by 49.4%, thus reaching an
inter-apheresis level (mean6SD) of 1736 37 mg/dL. This report suggests that a
combination therapy with evolocumab and lipoprotein-apheresis may have synergic
effects on circulating lipid levels. Its relevance as a highly effective treatment option
for hyperlipidemia in HeFH patients warrants further investigation in larger datasets.
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1 | INTRODUCTION
Familial hypercholesterolemia (FH) is an autosomal domi-
nant disorder of lipid metabolism, resulting from mutations
that most frequently involve the genes encoding for the low-
density lipoprotein (LDL) receptor, apolipoprotein B, or the
pro-protein convertase subtilisin/kexin type 9 (PCSK9) .1,2
The considerable increase of plasma LDL cholesterol levels
and the extra-plasmatic lipid depots are accounted among the
most characteristic phenotypic hallmarks of the disease. The
increased LDL cholesterol (LDL-C) levels per se and the life-
long exposure to inappropriately high lipid concentrations are
amongst the leading factors that significantly increase the risk
of atherosclerosis and overt cardiovascular diseases (CVD) in
patients with FH.2The phenotypic diagnosis of FH stands
on the finding of LDL-C concentrations above 190 mg/dL
(4.9 mmol/L) in individuals with a family history of hyper-
cholesterolemia and/or early coronary heart disease.2,3
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As recently reported in the consensus statement of the
European Atherosclerosis Society, a specific lipid-lowering
therapy targeted to effectively reduce the LDL-C levels
toward the normal range (or lower) could potentially reduce
the individual CVD risk to the same level of un-affected indi-
viduals from the general population.2 The advocated target
levels for both homozygous and heterozygous familial hyper-
cholesterolemia (HeFH) pointed to lowering LDL-C to <3.5
mmol/L (<135 mg/dL) in children and to <2.6 mmol/L
(<100 mg/dL) in adults, or< 1.8 mmol/L (<70 mg/dL) in
those at the highest risk.2,4
The pharmacological treatment of HeFH recognizes sta-
tins as pivotal therapeutic option. However, statin therapy
may be either not sufficiently effective, a situation also
referred to as “statin resistance,” or it may be accompanied
by side effects that are labeled as “statin intolerance.”
Among the latter, it should be accounted a phenomenon of
relatively rare occurrence, also known as statin-induced myo-
sitis, and characterized by muscle aches accompanied by
substantially elevated serum creatine kinase (CK) concentra-
tions.5 In these cases, the use of ezetimibe may be considered
as a second-line therapy, potentially followed by bile acid
sequestrants or fibrates, alone or in combination.
The recent advent of new classes of lipid-lowering
agents, which act by promoting the LDL catabolism via
monoclonal antibody-mediated inhibition of the activity of
pro-protein convertase subtilisin/kexin 9 (PCSK9), represents
a new opportunity for patients with HeFH and multiple statin
intolerance.6,7
A further therapeutic option stands on the physical
removal of cholesterol-rich lipoproteins from the blood
stream, a procedure dubbed as “lipoprotein apheresis,” which
has been demonstrated as a very effective strategy to treat
individuals with severe hyperlipidemia, including FH
patients resistant or intolerant to statin therapy.8,9
We herein report the clinical case of a HeFH patient with
intolerance to both statins and ezetimibe, in whom a combi-
nation therapy with evolocumab and lipoprotein apheresis
obtained a remarkable decrease of circulating lipid levels
toward the recommended ranges. Our observations point to
further studies investigating whether the combination of evo-
locumab and lipoprotein apheresis may act on hyperlipid-
emia with additive and synergic effects, thus eventually
supporting the relevance of this treatment strategy as a useful
therapeutic option in FH patients.
2 | CASE REPORT
A 49 years old female patient presented in the Outpatient
Lipid Clinic of the Verona University Hospital in May 2015.
A clinical diagnosis of HeFH was made in her adolescence
at 17 years of age, according to extant plasma LDL-C
concentrations above 300 mg/dL and to a positive family his-
tory of hypercholesterolemia and early coronary heart disease
(CHD) (father and paternal uncles). A genetic test conducted
in 2016 revealed a heterozygous mutation (c.1646 G>A; p.
Gly528Asp) in the exon 11 of the LDL-receptor (LDLR)
gene, pathogenic for HeFH.
With regard to the specific lipid-lowering therapy, a cho-
lestyramine p.o. bid treatment was promptly started at diag-
nosis in 1985 and it was continued until 1991. Starting from
1991, pravastatin 20 mg/die was initiated in place of the bile
acid sequestrants and this therapy was continued until 2000
with sporadic interruptions due to disabling muscle pain. In
2000, she was diagnosed as being affected by Cogan’s syn-
drome, a rare rheumatologic autoimmune disorder character-
ized by corneal and inner ear inflammation. The medical
therapy from this point onward also included salicylic acid
100 mg/die, methylprednisolone 4 mg/die, methotrexate
10 mg/week; pantoprazole 20 mg/die. In 2001, the lipid low-
ering therapy was potentiated by introducing atorvastatin
20 mg/die.
In 2002, during an intense physical training session, she
experienced acute muscle pain, rhabdomyolysis with massive
myoglobinuria and concomitant acute renal failure, which
required immediate hospitalization and hemodialysis. The lab-
oratory measurements at that time were as follows:
myoglobin5 159.8 ng/mL (normal range: 0–85 ng/mL),
CK> 100 000 U/L (normal range: 40–300 U/L), Lactate
dehydrogenase (LDH)5 7656 U/L (normal range: 122–222
U/L), aspartate aminotransferase (AST)5 2469 U/L (normal
range: 5–50 U/L), alanine aminotransferase (ALT)5 646 U/L
(normal range: 5–50 U/L). After a full clinical and laboratory
recovery from the incumbent situation was reached, the patient
was switched to an alternative combination therapy with fluva-
statin and ezetimibe. Unfortunately, muscle symptoms and CK
elevation reappeared. For these reasons, a nutraceutical treat-
ment with substances characterized by complementary lipid-
lowering properties was started in 2003, including red yeast
rice, policosanol, and berberine combined with folic acid,
astaxanthin, and coenzyme Q10 (Armolipid Plus® 1 cp/die).10
The patient came to our attention in December 2015. At
the physical examination: body weight5 68 kg, height5
158 cm, BMI5 27.3 kg/m2, ambulatory blood pressure5
120/84 mm Hg. No signs of xanthomas, corneal arcus, or
vascular bruits were detectable. The US-Doppler scan of the
carotid arteries showed bilateral punctiform calcific athero-
sclerosis without hemodynamic significant plaques at the
level of both internal and external carotid vessels. The esti-
mated calcium score (46.9 Agatston Units) at the CT-scan of
coronary arteries corresponded to the 97th percentile of indi-
viduals of same age, gender and ethnicity, free of cardiovas-
cular disease, and treated diabetes. Ultrasound scan of
abdominal aorta and arterial leg vessels did not reveal any
pathologic lesion. At the laboratory measurements on
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nutraceutical treatment: total-C5 522 mg/dL, LDL-C5
434 mg/dL, high-density lipoprotein cholesterol (HDL-C)5
84 mg/dL, triglycerides5 120 mg/dL, Lp(a) lipoprotein5 13
mg/dL.
Since the nutraceutical treatment did not obtain satisfac-
tory plasma lipid levels, a therapy with evolocumab 140 mg
sc every two weeks was started according to the scheme out-
lined in Figure 1 (period A). Total cholesterol, LDL-C,
HDL-C, and triglycerides concentrations were measured
every 8 weeks, as reported in Table 1. In this patient, suffer-
ing from a rheumatic disease, PCSK9 inhibitor treatment was
well tolerated. However, despite the evolocumab treatment,
the LDL-C plasma levels (mean6SD) remained above the
recommended target (3426 22 mg/dL; 221.2%).
Starting from May 2016, a treatment with lipoprotein
apheresis was added to the evolocumab therapy (Figure 1,
period B). Lipoprotein apheresis sessions were performed
every two weeks with heparin-induced LDL precipitation
apheresis (H.E.L.P. system Plasmat Futura-Braun, Melsun-
gen, Germany),11 treating 3000 mL of plasma for each ses-
sion (corresponding to 1.1 patient plasma volume).
Anticoagulation was performed with heparin (3000 IU as a
bolus and 2000 IU/h continuously). Plasma levels of total
cholesterol, LDL-C, HDL-C, and triglycerides were meas-
ured before and immediately after each apheresis session.
Evolocumab was administered immediately after apheresis
(140 mg every 2 weeks). In period B, lipoprotein apheresis
obtained a pronounced and rapid reduction of circulating LDL-
C levels at each session [pre-apheretic LDL-C (mean6 SD):
FIGURE 1 LDL-C plasma levels duringmonotherapy treatment
with evolocumab (140mgQW2) and during combination therapy with
evolocumab and HELP apheresis (Q2W). Blood sampling was performed
at baseline (0) and every 8 weeks during period A (evolocumab monother-
apy) and every two weeks (immediately before and after each apheresis
session) for period B (evolocumab1HELP apheresis combination ther-
apy). The average LDL-C levels are displayed on top of treatment period
A asmean6SD; the LDL-CAVG is displayed on top of period B and rep-
resents the time-averaged mean concentrations (CAVG) of LDL-C across
the apheresis sessions over 6 months
TABLE 1 Lipid and liver profile during evolocumab treatment in monotherapy (140 mg every two weeks)—Period A
Baseline 8 weeks 16 weeks 24 weeks
Total-C (mg/dL) 522 468 392 446
HDL-C (mg/dL) 84 81 70 67
LDL-C (mg/dL) 434 346 318 361
Triglycerides (mg/dL) 120 87 88 97
Lp(a) (mg/dL) 13 11 ND ND
AST (U/L) 25 19 29 13
ALT (U/L) 23 24 36 22
CK (U/L) 69 59 60 78
ND5 not determined.
FIGURE 2 LDL-C plasma levels immediately before and after the
first, second and third HELP apheresis session (Q2W). The graph shows
the results obtained during the first three HELP apheresis sessions and
highlights the considerable reduction of the pre-apheresis LDL-C concen-
tration (dark grey columns) that is achievedwithin the third apheresis ses-
sion. As clearly shown, compared to the basal (first apheresis) pre-
apheresis levels, the concentrations of pre-apheresis LDL-C displayed a
remarkable reduction of 29% and 41% at the second and third apheresis
session, respectively
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2166 47 mg/dL; post-apheretic LDL-C: 576 13 mg/dL; D%
273.2%], with a progressive decline of pre-apheretic LDL-C
spanning from 29% to 41% after two and four weeks of treat-
ment, respectively (Figure 2). From this point onward the
inter-apheresis LDL-C levels remained substantially constant
around 1616 15 mg/dL. No adverse effect was reported in
any of the apheresis sessions.
Inter-apheresis LDL-C levels represent the most accurate
measurement of the individual total exposure to LDL-C and
it is obtained by calculating the time-averaged concentration
between consecutive sessions of lipoprotein apheresis.12
Therefore, the time-averaged mean concentrations (CAVG) of
LDL-C herein presented were calculated by applying the fol-
lowing formula devised by Kroon et al.12
CAVG5CMIN10:73 CMAX2CMINð Þ
where CMAX is the pre-treatment level and CMIN the levels
immediately after apheresis.
Accordingly, as shown in Figure 1 (period B), the
mean6 SD pre-apheresis and post-apheresis LDL-C levels
were 2166 47 mg/dL (LDL-CMAX) and 576 13 mg/dL
(LDL-CMIN), respectively. Overall, the resulting LDL-C
inter-apheresis levels (LDL-CAVG) over 6 months of combi-
nation therapy were 1736 37 mg/dL, corresponding to a
49.4% reduction, as compared to the average LDL-C levels
obtained during the evolocumab monotherapy (period A).
3 | DISCUSSION
The inhibitors of PCSK9 can be offered as a valuable and
alternative therapeutic option in patients with statin intoler-
ance or resistance to the lipid lowering therapy. In the
ODYSSEY ALTERNATIVE trial, the 24-week administra-
tion of alirocumab, a human PCSK9 monoclonal antibody,
obtained a reduction of mean LDL-cholesterol levels by 45%
in patients with well-documented statin intolerance.6 In the
GAUSS-3 trial, the mean percent change in LDL-C levels
after 24 weeks with evolocumab was 252.8% among
patients with statin intolerance.7 In our case report, in a
patient with severe hypercholesterolemia and a rheumatic
disease, evolocumab given for 24 weeks reduced LDL-C lev-
els by 21.2%. Therefore, since the LDL-C levels decreased
<25%, this patient could be defined “hyporesponder,”
according to similar clinical experience recently described by
Galema-Boers et al.13
Lipoprotein apheresis is currently the best treatment
option to bring patients with severe forms of hypercholester-
olemia (such as HeFH) closer to target LDL-C levels.8 In
patients on lipoprotein apheresis therapy, the most accurate
measurement of the individual total exposure to LDL-C is
obtained from calculating the interval mean or time-averaged
concentration between consecutive procedures,12 whereas the
pre-apheresis concentrations reflect the maximal values
reached during this form of treatment.14 Using pre-treatment
levels, the documented long-term reductions in LDL-C in
HeFH patients were approximately 30% after 6 months of
therapy.14 In our case report, the pre-apheresis LDL-C levels
showed a remarkable reduction of about 41% after 4 weeks
of combination therapy, as compared to the LDL-C obtained
during the evolocumab monotherapy (Figure 2). Lipoprotein
apheresis, along with its intrinsic lipid lowering action, also
exerts effects on the individual inflammatory profile as well
as on the coagulative system, hemorheological functions, and
fibrinolysis.15 These pleiotropic effects may have long-term
effects on the individual cardiovascular risk profile, particu-
larly by reducing the pro-inflammatory status that usually
accompanies metabolic disorders.
The striking reduction of LDL-C levels obtained in this
patient affected by Cogan’s syndrome may suggest that the
combination of lipoprotein apheresis with evolocumab ther-
apy enhances the effects of the PCSK9 inhibitor on LDL
catabolism and may have dampened the lipid rebound effect
of the first three lipoprotein apheresis sessions. However, it
should be noted that, despite the remarkable response to the
combination therapy, the recommended LDL-C target in this
high-risk individual was not reached. Although it would be
advisable to intensify the treatment by weekly apheresis ses-
sions, this was not practicable as they would have conflicted
with the working schedule of our patient. With regard to
other pharmacologic treatment options currently available for
the treatment of FH in our country, it should be pointed out
that lomitapide, a small molecule inhibitor of microsomal tri-
glyceride transfer protein, is currently licensed for homozy-
gous FH, but not for HeFH. Nonetheless, despite the
cardiovascular risk profile in this patient remains high, it is
reasonably expectable that the combination therapy of lipo-
protein apheresis with evolocumab will eventually be effec-
tive to relent/prevent the development of a major
cardiovascular event.
This case report taught us that evolocumab treatment in
an individual with HeFH and statin intolerance was effective
at remarkably reducing the LDL-C levels without side
effects, particularly when coupled with lipoprotein apheresis.
Evolocumab may not be sufficient to reach the recommended
LDL-C target neither as monotherapy, nor in combination
with lipoprotein apheresis, at least in this clinical case. As a
possible explanation for the relatively low LDL-C percent
reduction with evolocumab monotherapy (–21.2%), we may
point to the concomitant immunosuppressive therapy for the
Cogan’s syndrome and to the hyperlipidemic effect of meth-
ylprednisolone.16 However, although we did not test the
effect of lipoprotein apheresis alone in our patient, it is possi-
ble that the combination of evolocumab and lipoprotein
apheresis may have a synergic effect on the resulting circu-
lating lipid levels. Further ad hoc studies are needed to
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specifically test this hypothesis by administering lipoprotein
apheresis alone, evolocumab alone, and then combine the
two treatments. It should also be noted that the costs associ-
ated with increased frequency of apheresis sessions is consid-
erably higher than the combination therapy herein proposed.
Our observations should also be interpreted in light of the
individual risk profile of this specific patient. In absolute
terms, the combination therapy with evolocumab and lipo-
protein apheresis was able to reduce the LDL-C by approxi-
mately 60%, a result that is particularly relevant, given the
considerably high basal LDL-C levels detected in this patient
at the time of first evaluation at our center.
In light of the relevance of this combination therapy as a
useful therapeutic option to reach the recommended lipid tar-
gets in high risk patients with HeFH, further investigations
are needed to confirm our observations in larger datasets and
to test its cardiovascular benefits and the potential systematic
application in high-risk patients resistant or intolerant to con-
ventional therapies.
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